Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Christoph Röllig, MD MSC, Michael Kramer, M.Sc., Christoph Schliemann, Jan-Henrik Mikesch, MD, Björn Steffen, MD, Alwin Krämer, MD, Tim Sauer, MD, Mathias Hänel, MD, Regina Herbst, MD, Kerstin Schäfer-Eckart, MD, Richard Noppeney, MD, Edgar Jost, MD, Tim H Brümmendorf, MD, Stefan W Krause, MD, Volker Kunzmann, MD PhD, Hermann Einsele, MD, Sebastian Scholl, Andreas Hochhaus, MD, Lars R. Fransecky, MD, Martin Kaufmann, MD, Andreas Neubauer, MD, Dirk Niemann, MD, Markus Schaich, MD, Norbert Frickhofen, MD, Alexander Kiani, Frank Heits, MD, Ulrich Krümpelmann, Ulrich Kaiser, MD, Johannes Kullmer, Maxi Wass, MD, Stefan Klein, MD, Malte Von Bonin, Jan Moritz Middeke, MD, Christian Thiede, MD, Friedrich Stoelzel, MD, Johannes Schetelig, MDMSc, Gerhard Ehninger, MD, Claudia D Baldus, Carsten Müller-Tidow, MD, Uwe Platzbecker, Hubert Serve, MD, Martin Bornhäuser, MD

Blood (2019) 134 (Supplement_1): 13.

https://doi.org/10.1182/blood-2019-123717

Published: 2019

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1)

Georg Evers, MD, Dietrich W. Beelen, Jan Braess, MD, Cristina Sauerland, Hans-Jochem Kolb, MD, Albrecht Reichle, MD, Ernst Holler, MD, Rainer Schwerdtfeger, MD, Renate Arnold, MD, Christoph Scheid, MD, Utz Krug, MD, Carsten Müller-Tidow, MD, Christoph Schliemann, MD, Jan-Henrik Mikesch, MD, Georg Lenz, Bernhard J. Wörmann, MD, Wolfgang Hiddemann, Wolfgang E. Berdel, MD, Matthias Stelljes, MD

Blood (2018) 132 (Supplement 1): 4649.

https://doi.org/10.1182/blood-2018-99-116964

Published: 2018

Journal Articles

High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years)

Jan-Henrik Mikesch, MD, Christina Sauerland, Dipl.-Math, Tobias Herold, MD, Dennis Görlich, Eike Bormann, Wolfgang Hartmann, MD, Christoph Schliemann, MD, Bernhard J Wörmann, MD, Wolfgang Hiddemann, Karsten Spiekermann, MD, Matthias Stelljes, Utz Krug, MD, Carsten Muller-Tidow, MD, Thomas Büchner, MD, Wolfgang E Berdel, MD, Maria Francisca Arteaga, PhD

Blood (2016) 128 (22): 2840.

https://doi.org/10.1182/blood.V128.22.2840.2840

Published: 2016

Journal Articles

Functional Dissection and Targeting Of Bmi1 Independence Of MN1 Leukemia

Jan-Henrik Mikesch, MD, Maria F Arteaga, PHD, Clemence Virely, PHD, Chi Wai Eric So, PHD

Blood (2013) 122 (21): 474.

https://doi.org/10.1182/blood.V122.21.474.474

Published: 2013

Journal Articles

Discovery of Critical Functions of Histone Demethylase, PHF8, in Mediating ATRA Response in APL

Maria Francisca Arteaga, PhD, Jan-Henrik Mikesch, MD, Chi Wai Eric So, PhD

Blood (2011) 118 (21): 226.

https://doi.org/10.1182/blood.V118.21.226.226

Published: 2011

NARROW

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1)

High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years)

Functional Dissection and Targeting Of Bmi1 Independence Of MN1 Leukemia

Discovery of Critical Functions of Histone Demethylase, PHF8, in Mediating ATRA Response in APL

Email alerts

ASH Publications

American Society of Hematology

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1)

High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years)

Functional Dissection and Targeting Of Bmi1 Independence Of MN1 Leukemia

Discovery of Critical Functions of Histone Demethylase, PHF8, in Mediating ATRA Response in APL

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only